1. Introduction {#sec1-ijms-18-01434}
===============

The microtubule cytoskeleton is an extensive network of filaments that span the cell interior. Microtubules are composed of αβ-tubulin heterodimers that associate to form protofilaments, which then laterally associate to form microtubules \[[@B1-ijms-18-01434]\]. These highly dynamic structures are constantly lengthening and shortening throughout all phases of the cell cycle by the addition and removal of tubulin heterodimers at the microtubule ends. The manner in which tubulin heterodimers are orientated in microtubules gives rise to a polar molecule that differs in its structure and kinetics at each end of the microtubule \[[@B1-ijms-18-01434]\]. The dynamics of tubulin heterodimer addition and release are slower at the minus end of the microtubule, which terminates in α-tubulin proteins, compared with the plus end of the microtubule, which terminates with β-tubulin proteins capped in the GTP-bound state \[[@B2-ijms-18-01434],[@B3-ijms-18-01434]\]. Therefore, microtubules are nucleated at their minus ends while their plus ends more dynamically lengthen and shorten \[[@B1-ijms-18-01434]\]. The transition of a microtubule from a period of lengthening to one of shortening is termed catastrophe, while the restoration of microtubule lengthening following a period of shortening is termed rescue. Any single microtubule will dynamically transition between any of these phases over its lifetime. In addition, interactions between microtubules and an extensive network of proteins regulate their stability and dynamicity \[[@B4-ijms-18-01434]\]. Readers are referred to several extensive reviews of microtubule dynamics and its regulation for more detailed description of these processes \[[@B5-ijms-18-01434],[@B6-ijms-18-01434]\].

During interphase, the majority of microtubules are nucleated at the centrosome and radiate towards the cell periphery \[[@B3-ijms-18-01434]\]. One of the major functions of interphase microtubules is their involvement in maintenance of cell shape and trafficking of proteins and organelles \[[@B4-ijms-18-01434]\]. Motor proteins utilize the microtubule cytoskeleton for translocating cell components on microtubule tracks, and co-ordination of this process occurs by protein--protein interactions with other adaptor proteins \[[@B4-ijms-18-01434]\].

During mitosis, the microtubule network remodels to form the mitotic spindle, and the dynamic nature of the microtubule filaments enables correct segregation of the chromosomes. Failure to correctly attach or segregate the chromosomes initiates cell cycle arrest at the mitotic checkpoint, and can lead to the initiation of apoptosis \[[@B7-ijms-18-01434]\]. The tubulin-binding agent (TBA) class of chemotherapeutics, which include taxanes, *vinca* alkaloids and epothilones, directly target β-tubulins to suppress the dynamics of spindle microtubules, thereby disrupting chromosomal segregation to induce cell cycle arrest and cell death \[[@B8-ijms-18-01434]\]. Particular classes of tubulin binding agents have also more rarely been detected binding to both α- and β-tubulin proteins at the interface between two dimers \[[@B9-ijms-18-01434]\].

In humans, microtubules are composed of mixed combinations of eight α-tubulin isotypes and seven β-tubulin isotypes \[[@B10-ijms-18-01434]\]. The different tubulin isotypes are encoded by different genes on distinct chromosomes and possess specific tissue and developmental distributions \[[@B11-ijms-18-01434],[@B12-ijms-18-01434]\]. Tubulin isotypes share a high degree of structural homology but are distinguished from one another by highly divergent sequences at their carboxy-terminal (C-terminal) tail \[[@B13-ijms-18-01434]\]. The N-terminal and intermediate domains of the protein form a highly conserved and rigid globular tubulin body that stack to form protofilaments, while the C-terminal tail of the protein is a highly disordered peptide 18--24 amino acids in length. These C-terminal tails are sites for post-translational modifications and mediate interactions with a range of proteins \[[@B4-ijms-18-01434]\], which collectively impart unique functionality to each tubulin isotype \[[@B4-ijms-18-01434]\]. A co-ordinated cohort of chaperones and post-chaperonin cofactors assists the folding of nascent peptides into the highly rigid globular fold adopted by the tubulin body while also controlling the formation of tubulin heterodimers \[[@B14-ijms-18-01434],[@B15-ijms-18-01434]\]. Microtubules do not readily accommodate deviations in the tubulin fold and therefore obtaining correct tubulin fold is critical in regulating microtubule structure and dynamics. Furthermore, the associations of tubulins with their post-chaperonin cofactors also regulates the dynamic exchange of tubulin heterodimers between the polymerised and soluble tubulin pools and enables this process to operate far from equilibrium \[[@B14-ijms-18-01434]\]. However, the tubulin globular fold is highly conserved and how tubulin folding might contribute to regulating tubulin isotype composition is largely unknown.

In a range of cancers with different primary sites, the tubulin isotype composition of cancer cells is perturbed compared with the surrounding healthy tissue. This aberrant expression involves increased or decreased expression of one or more tubulin isotypes, as well as the expression of tubulin isotypes that are not normally detectable in the healthy tissue \[[@B16-ijms-18-01434]\]. Importantly, this aberrant expression of different tubulin isotypes correlates with patient outcome and treatment response. This review focuses on the current knowledge of the role of tubulin isotypes in chemotherapy drug resistance, disease aggressiveness and tumour biology. The majority of studies in this field have focussed on the importance of β-tubulin proteins, largely due to the specificity of tubulin-binding agents for β-tubulin proteins together with a dearth of tools to interrogate the importance of α-tubulin isotypes in this context. However, undoubtedly, α-tubulin isotypes, similar to β-tubulin isotypes, will also be increasingly associated with cancer patient outcome with further advances in our understanding of tubulin and tumour biology.

2. Tubulin Isotype Expression in Cancer {#sec2-ijms-18-01434}
=======================================

Altered expression of tubulin isotypes has been observed in a range of cancers. Analysis of clinical specimens has shown that high expression of several tubulin isotypes, namely βI-, βII-, βIII-, βIVa-, and βV-tubulin, correlates with aggressive clinical behaviour, chemotherapy drug resistance and poor patient outcome in many cancers ([Table 1](#ijms-18-01434-t001){ref-type="table"}). Although tubulin protein levels are predominantly regulated post-translationally such that protein levels of tubulin isotypes poorly reflect the transcript levels \[[@B16-ijms-18-01434]\], changes in the tubulin isotype expression have been characterised at both the transcript \[[@B16-ijms-18-01434],[@B17-ijms-18-01434],[@B18-ijms-18-01434]\] and protein level \[[@B16-ijms-18-01434],[@B19-ijms-18-01434],[@B20-ijms-18-01434],[@B21-ijms-18-01434],[@B22-ijms-18-01434],[@B23-ijms-18-01434],[@B24-ijms-18-01434],[@B25-ijms-18-01434],[@B26-ijms-18-01434],[@B27-ijms-18-01434],[@B28-ijms-18-01434]\].

Aberrant βIII-tubulin expression has been the most comprehensively characterised of the tubulin isotypes in this context and since the first report of high expression levels of βIII-tubulin in paclitaxel-resistant ovarian cancer \[[@B29-ijms-18-01434]\], growing clinical evidence indicates that βIII-tubulin expression is involved in resistance to taxanes and *vinca* alkaloids in a range of tumour types, including lung, breast, ovarian and gastric cancers ([Table 1](#ijms-18-01434-t001){ref-type="table"}). While the majority of these studies have identified that high expression of this isotype correlates with poor patient outcome, the opposite effect has been noted in ovarian clear cell adenocarcinoma ([Table 1](#ijms-18-01434-t001){ref-type="table"}). This contrasting prognostic and predictive value of βIII-tubulin expression in taxane response in ovarian cancer subtypes suggests a tumour-type specificity that is incompletely understood. Multiple studies have shown that the expression of βIII-tubulin correlates with poor response to taxane-based chemotherapy and a correlation of βIII-tubulin positivity with more advanced clinical stage of ovarian cancer \[[@B19-ijms-18-01434],[@B20-ijms-18-01434],[@B21-ijms-18-01434],[@B28-ijms-18-01434],[@B29-ijms-18-01434],[@B30-ijms-18-01434],[@B31-ijms-18-01434],[@B32-ijms-18-01434],[@B33-ijms-18-01434]\]. In contrast, in ovarian clear cell adenocarcinoma, overexpression of βIII-tubulin predicts a good response to taxane-based chemotherapy and, among patients treated with taxane-based chemotherapy, cases with higher βIII-tubulin expression were associated with a significantly more favourable prognosis compared with those having lower βIII-tubulin expression \[[@B34-ijms-18-01434]\]. These contrasting findings reveal the complexity by which altered βIII-tubulin expression may influence TBA responsiveness, and highlight the need to understand the factors determining the prognostic and predictive value of tubulin isotype expression in TBA efficacy.

Altered expression of βI-, βII-, βIVa-and βV-tubulins has also been associated with resistance to TBAs in a number of cancer types ([Table 1](#ijms-18-01434-t001){ref-type="table"}). However, to date, clinical studies investigating these specific tubulin isotypes in cancer have been limited and further investigation is required to define their contribution to drug resistance phenotypes.

While mutations in the β-tubulin isotypes are not clinically prevalent \[[@B35-ijms-18-01434]\], a recent study in breast cancer patients identified several mutations in βI-, βIIa- and βIVb-tubulin isotypes that modify the isotype sequence to resemble that of βIII-tubulin, and the authors propose that these structural permutations are likely to impact clinical outcome in a similar manner to altered βIII-tubulin expression \[[@B36-ijms-18-01434]\].

β-Tubulin isotype expression in tumour-associated stroma has not been extensively studied. One recent study identified that treatment of ovarian cancer with neoadjuvant chemotherapy primarily reduced the βIII-tubulin expression in stroma, and that a reduction in βIII-tubulin expression levels in both the tumoural and stromal compartment were each associated with increased survival \[[@B28-ijms-18-01434]\]. How changes in the tubulin isotype composition of stroma may influence disease progression and drug response warrants further investigation.

2.1. Tubulin Isotypes and Drug Resistance {#sec2dot1-ijms-18-01434}
-----------------------------------------

Clinical observations that altered expression of β-tubulin isotypes in cancer are associated with altered sensitivity to TBAs are supported by in vitro studies noting altered expression of βII-, βIVa-, βIVb and βV-tubulin isotype expression in a range of drug-resistant cancer cell lines \[[@B29-ijms-18-01434],[@B40-ijms-18-01434],[@B49-ijms-18-01434],[@B50-ijms-18-01434],[@B51-ijms-18-01434],[@B52-ijms-18-01434],[@B53-ijms-18-01434],[@B54-ijms-18-01434],[@B55-ijms-18-01434],[@B56-ijms-18-01434],[@B57-ijms-18-01434],[@B58-ijms-18-01434],[@B59-ijms-18-01434]\]. Forced genetics approaches further substantiate these findings and have illustrated that β-tubulin isotypes differentially affect the efficacy of TBAs in a cell type-dependent manner \[[@B56-ijms-18-01434]\]. βII-Tubulin and βIII-tubulin isotypes confer resistance to taxanes in non-small cell lung cancer (NSCLC) cells, while suppression of βII-tubulin or βIVb-tubulin sensitises NSCLC \[[@B49-ijms-18-01434],[@B50-ijms-18-01434]\] and pancreatic cancer cells \[[@B60-ijms-18-01434]\] to *vinca* alkaloids. Conversely, suppression of βII-tubulin specifically sensitises NSCLC cells to epothilone B \[[@B49-ijms-18-01434],[@B50-ijms-18-01434]\]. These findings conflict with other studies showing that βIII-tubulin but not βI-tubulin or βII-tubulin expression affected epothilone sensitivity in NSCLC and breast cancer cell lines \[[@B61-ijms-18-01434]\]. Conversely in ovarian cancer cells, suppression of βII-tubulin does not sensitise cells to taxanes or *vinca* alkaloids but does sensitise them to the non-taxoid microtubule stabilising agents laulimalide and peroluside \[[@B56-ijms-18-01434]\]. Further delineation of the factors that determine the specificity of the tubulin isotypes for influencing TBA responses across different cell types is required.

Compared with other β-tubulin isotypes, the βIII-tubulin isotype has been the most extensively studied tubulin isotype for its role in drug resistance, and growing clinical ([Table 1](#ijms-18-01434-t001){ref-type="table"}) and in vitro evidence supports its role in mediating broad-spectrum drug resistance. In vitro studies have identified a role for this isotype in mediating resistance to DNA damaging agents, antimetabolites and topoisomerase inhibitors in NSCLC cells, melanoma and pancreatic cancer cells in addition to influencing taxane and *vinca* alkaloids resistance \[[@B49-ijms-18-01434],[@B62-ijms-18-01434],[@B63-ijms-18-01434],[@B64-ijms-18-01434],[@B65-ijms-18-01434],[@B66-ijms-18-01434]\], suggesting that this isotype plays a broader role in chemotherapy resistance mechanisms that extend beyond its function as a binding target for TBAs. This is supported by observations that βIII-tubulin expression levels do not equally modulate the sensitivity of cancer cells to all TBA subclasses \[[@B56-ijms-18-01434]\].

Other studies overexpressing β-tubulin isotypes have yielded conflicting results. Overexpression of βIII- or βV-tubulin in CHO cells increases the resistance of these cells to paclitaxel \[[@B52-ijms-18-01434],[@B67-ijms-18-01434]\] while other studies indicate that overexpression of βI-, βII-, and βIVb-tubulin does not affect TBA resistance in these cells \[[@B68-ijms-18-01434]\]. In addition, overexpression of βIII-tubulin failed to confer resistance to TBAs in prostate cancer \[[@B69-ijms-18-01434]\]. These discrepancies may reflect the complex autoregulation of β-tubulin isotype expression \[[@B70-ijms-18-01434]\], their collective and combinatorial influence on drug sensitivity \[[@B71-ijms-18-01434]\], and the importance of treatment regime and disease stage in the clinical observations associated with altered β-tubulin isotype expression \[[@B72-ijms-18-01434]\]. While forced genetics approaches have yielded important insight into the contribution of β-tubulin isotypes in drug resistance, more advanced understanding of the mechanisms that drive altered isotype expression and tools to manipulate these endogenous regulatory processes in cancer cells would make valuable contributions to the field.

2.2. Microtubule Dynamics and Chemotherapy Resistance {#sec2dot2-ijms-18-01434}
-----------------------------------------------------

The most characterised mechanisms of action of TBAs are their drug-induced suppression of microtubule dynamics, the induction of cell cycle arrest and the induction of cell death \[[@B8-ijms-18-01434]\]. The different dynamic properties of the β-tubulin isotypes may alter the sensitivity of microtubules to these agents and thereby explain how altered β-tubulin isotype composition impacts drug responsiveness in the clinical and preclinical setting. In cell-free studies using isolated tubulin, microtubules composed of the βIII-tubulin isotype are more dynamic than microtubules composed of βII or βIV-tubulin isotypes, which are associated with more stable microtubules \[[@B73-ijms-18-01434],[@B74-ijms-18-01434],[@B75-ijms-18-01434]\]. In this manner, the presence of βIII-tubulin may support microtubule dynamics even in the presence of TBAs, thus contributing to resistance to the primary mechanism of action of this drug class. More recent studies indicate that tubulin isotypes differ principally in their catastrophe frequency \[[@B76-ijms-18-01434],[@B77-ijms-18-01434],[@B78-ijms-18-01434]\]. For example, microtubules composed of βIII-tubulin have a 1.5--3 fold higher catastrophe frequency compared with those composed of βII-tubulin \[[@B78-ijms-18-01434]\]. In this respect, altered expression of β-tubulin isotypes may fine-tune the catastrophe frequency of the microtubule, thereby altering basal microtubule dynamics and the impact of chemotherapeutics that suppress microtubule dynamics. Microtubule-associated proteins can further influence microtubule dynamics in a tubulin isotype-specific manner. In the presence of microtubule-associated proteins, microtubule assembly is inhibited and proceeds faster in the presence of βIII-tubulin compared with other isotypes \[[@B79-ijms-18-01434],[@B80-ijms-18-01434],[@B81-ijms-18-01434]\]. Therefore, the collective influence of the tubulin isotype composition and the microtubule associated proteins that spatiotemporally interact with the microtubule network may regulate basal microtubule dynamics and the response of the microtubule network to TBAs in cancer cells.

This complexity in the regulation of microtubule dynamics may explain why observations that the β-tubulin isotype composition intrinsically modulates microtubule dynamics in cell-free systems have not been unequivocally supported by observations within the more complex intracellular environment. In the absence of tubulin-binding agents (TBAs), depletion of βIII-tubulin does and does not influence interphase microtubule dynamics in mammary epithelium and lung cancer cells, respectively, while βII-tubulin levels do not affect microtubule dynamics in the latter cell type \[[@B82-ijms-18-01434],[@B83-ijms-18-01434]\]. However, in the presence of TBAs, suppression of βIII-tubulin expression consistently reduces the efficacy of TBAs (ixabepilone, eribulin, paclitaxel, and vincristine) in suppressing microtubule dynamics in a number of cell types, concurring with observations in cell-free systems \[[@B74-ijms-18-01434],[@B82-ijms-18-01434],[@B84-ijms-18-01434],[@B85-ijms-18-01434],[@B86-ijms-18-01434],[@B87-ijms-18-01434],[@B88-ijms-18-01434]\]. Conversely, observations that the βIII-tubulin expression level alters the sensitivity of microtubules to the destabilising effects of colchicine \[[@B89-ijms-18-01434],[@B90-ijms-18-01434]\] could not be recapitulated in breast cancer cell lines \[[@B88-ijms-18-01434]\]. While microtubules composed of βIV-tubulin are also more resistant to paclitaxel-mediated microtubule stabilisation and α-βII-tubulin microtubules are most sensitive to vinblastine in the presence of MAPs in cell-free systems compared with other tubulin isotypes \[[@B79-ijms-18-01434],[@B80-ijms-18-01434]\], these findings have not been confirmed in the more complex intracellular environment.

Differences in the TBA-binding properties of different tubulin isotypes may partially explain how altered isotype composition may give rise to a drug resistance phenotype. Microtubules composed of mixed tubulin isotypes or purified βII-tubulin proteins bind fewer taxol molecules compared with βIII-tubulin or βIV-tubulin \[[@B74-ijms-18-01434]\]. Conversely, the microtubule destabilising agents vincristine, vinorelbine and nocodazole interact more weakly with βIII-tubulin than with other β-tubulin isotypes in vitro, while nocodazole, similar to colchicine, binds most strongly to α-βIV-tubulin \[[@B81-ijms-18-01434],[@B91-ijms-18-01434]\]. Estramustine \[[@B92-ijms-18-01434]\] and eribulin \[[@B85-ijms-18-01434]\] also bind to microtubules composed of α-βIII-tubulin less efficiently than other β-tubulin isotypes \[[@B92-ijms-18-01434]\]. Therefore, altered tubulin isotype expression in cancer cells may directly contribute to the sensitivity of the microtubule cytoskeleton to tubulin-binding chemotherapy agents to subsequently impact treatment efficacy.

Other classes of chemotherapy agents have also been observed to directly interact with tubulin proteins. Although DNA-damaging agents are not canonical tubulin binding agents, cisplatin is capable of binding to tubulin through the protein's GTP site \[[@B93-ijms-18-01434]\] and inhibit microtubule assembly in cell free systems \[[@B94-ijms-18-01434]\]. Whether this effect explains the role for βIII-tubulin in conferring resistance to DNA-damaging agents \[[@B61-ijms-18-01434],[@B63-ijms-18-01434],[@B66-ijms-18-01434],[@B95-ijms-18-01434]\] has not been directly examined.

Conformational changes induced upon drug binding and differences in the residues that stabilise drug binding are believed to account for the impact of different tubulin isotype compositions on the dynamic and drug sensitivity behaviours of microtubules \[[@B77-ijms-18-01434],[@B90-ijms-18-01434],[@B96-ijms-18-01434],[@B97-ijms-18-01434],[@B98-ijms-18-01434]\]. Recent evidence indicates that the unique dynamic characteristics of the individual isotypes are encoded within the tubulin body, despite their high degree of structural homology in this region of the tubulin protein \[[@B78-ijms-18-01434]\]. The intermediate domain of the tubulin body has been proposed to regulate microtubule dynamics through its conformational state and by coupling the tubulin conformation to the tubulin GTP hydrolysis cycle \[[@B99-ijms-18-01434],[@B100-ijms-18-01434]\]. In addition, the isotype defining region of the tubulin proteins, the C-terminal tail, which regulates microtubule dynamics through interactions with the intermediate domains of neighbouring tubulin isotypes to destabilise microtubules \[[@B101-ijms-18-01434],[@B102-ijms-18-01434],[@B103-ijms-18-01434],[@B104-ijms-18-01434],[@B105-ijms-18-01434],[@B106-ijms-18-01434],[@B107-ijms-18-01434],[@B108-ijms-18-01434],[@B109-ijms-18-01434],[@B110-ijms-18-01434],[@B111-ijms-18-01434],[@B112-ijms-18-01434],[@B113-ijms-18-01434],[@B114-ijms-18-01434],[@B115-ijms-18-01434]\] may also contribute to the dynamic features of microtubules through differences in the conformational space covered by these flexible regions of the protein and by interacting with neighbouring tubulin heterodimers in an isotype-specific manner \[[@B101-ijms-18-01434],[@B102-ijms-18-01434],[@B103-ijms-18-01434],[@B116-ijms-18-01434]\]. While the disordered nature of the tubulin C-terminal tail has hindered direct experimental characterisation of tail-body interactions proposed by these molecular dynamics simulations, evidence that the C-terminal tail region differentially affects microtubule assembly between isotypes \[[@B117-ijms-18-01434]\] supports the notion that this region of the protein may significantly contribute to isotype-specific microtubule dynamics. Similarly, post-translational modifications and isotype-specific interaction with microtubule associated protein interactions in this C-terminal tail region may also confer different dynamic properties to the tubulin isotypes \[[@B118-ijms-18-01434]\]. Furthermore, the ability of tubulin-binding agents to preferentially relocalise subsets of plus-end tracking proteins \[[@B119-ijms-18-01434]\] may amplify the influence of particular tubulin isotypes on tubulin-binding agent activity.

Overall, differences in the sensitivity of different tubulin isotypes on the ability of TBAs to suppress microtubule dynamics may partially explain the associations between altered isotype composition and resistance to these agents.

2.3. Tubulin Isotypes in Tumour Biology {#sec2dot3-ijms-18-01434}
---------------------------------------

While it is clear from the studies described in the preceding section that the β-tubulin isotype composition affects microtubule dynamics and the sensitivity of microtubules to TBAs, this simplistic model of drug resistance fails to explain how an individual β-tubulin isotype, βIII-tubulin might confer resistance to diverse non-tubulin targeting agents such as DNA-damaging agents, antimetabolites and topoisomerase inhibitors \[[@B61-ijms-18-01434],[@B63-ijms-18-01434],[@B66-ijms-18-01434],[@B95-ijms-18-01434]\]. In addition, βIII-tubulin expression regulates the tumourigenic and metastatic potential of NSCLC and pancreatic cells in vivo \[[@B31-ijms-18-01434],[@B63-ijms-18-01434],[@B66-ijms-18-01434],[@B120-ijms-18-01434]\], further supporting a broader role for this β-tubulin isotype in tumour biology. The importance of βIII-tubulin in the progression of the primary tumour appears to be cancer specific, since suppression of βIII-tubulin did not affect primary tumour growth in a breast cancer model \[[@B121-ijms-18-01434]\].

Intracellular processes that enable tumour progression also facilitate drug resistance, thereby providing a common foundation from which altered expression of β-tubulin isotypes may impact both drug resistance and disease aggressiveness. Central to these are oncogenic, stress response and cell death signalling processes that enable cancer cells to survive and proliferate within the harsh tumour microenvironment and in response to drug treatment. Involvement of β-tubulin isotypes in the signalling processes that regulate the progression of the primary tumour are discussed in more detail below.

3. Tubulin and Oncogenic Signalling {#sec3-ijms-18-01434}
===================================

Although tubulin isotypes are aberrantly expressed in many types of cancers, there is no evidence to support their classification as an oncogene, which by definition is a gene that when genetically altered, enables it to drive the transformation of normal cells. Nevertheless, several studies have shown that βIII-tubulin may serve as downstream targets of several known oncogenic pathways. βIII-Tubulin is induced by mutant Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) expression and also in response to Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (EGFR) stimulation by a post-translational mechanism \[[@B24-ijms-18-01434]\]. Correlations between high βIII-tubulin expression and KRAS mutant tumours in NSCLC \[[@B24-ijms-18-01434]\] suggests that βIII-tubulin may potentially contribute to Ras-induced transformation, although this hypothesis remains to be investigated in vivo.

βIII-Tubulin expression has also been associated with the phosphatase and tensin homolog (PTEN) signalling pathway. In prostate cancer, *PTEN* deletions correlate with elevated βIII-tubulin expression in prostate cancer, suggesting that altered βIII-tubulin expression may result from PTEN-mediated reprogramming events in tumour initiation \[[@B48-ijms-18-01434]\]. The same study also showed that βIII-tubulin expression is strongly associated with ERG expression and *TMPRSS2:ERG* rearrangement in prostate cancer \[[@B48-ijms-18-01434]\]. In colon cancer, Xiao and colleagues reported that inhibiting the Protein kinase B (AKT) or the extracellular-signal-regulated kinase (ERK) signalling pathways downregulates expression of βIII-tubulin, indicating that βIII-tubulin could be regulated by both AKT and ERK pathways \[[@B122-ijms-18-01434]\]. Suppression of βIII-tubulin expression in NSCLC cells has been demonstrated to increase PTEN expression, which acts upstream of AKT to inhibit its phosphorylation (activation) \[[@B123-ijms-18-01434]\]. Functionally, this correlated with increased sensitivity to anoikis (a form of programmed cell death) and reduced tumour growth in mice \[[@B123-ijms-18-01434]\]. The PTEN/phosphoinositide 3-kinase (PI3K)/AKT signalling axis is commonly dysregulated in tumour cells and is strongly implicated in tumourigenesis and metastasis to promote cancer cell survival and proliferation during tumour progression and in response to chemotherapy agents. Further delineation of how βIII-tubulin may modulate the activity of this important signalling pathway is required.

Overall, these observations raise the notion that tubulin isotypes may act as permissive mediators of oncogenic signalling to enable tumour progression. The context in which they contribute to oncogenic signalling and the impact of their involvement remains to be comprehensively characterised for different disease settings.

4. Tubulin and Microenvironmental Stress Response {#sec4-ijms-18-01434}
=================================================

4.1. Tubulin and Hypoxia {#sec4dot1-ijms-18-01434}
------------------------

Dramatic microtubule remodelling occurs in hypoxic conditions, suggesting an important role for the microtubule network in hypoxic adaptation \[[@B124-ijms-18-01434],[@B125-ijms-18-01434],[@B126-ijms-18-01434]\]. While the importance of specific tubulin isotypes in this context remain to be fully defined, emerging evidence supports a specific role for βIII-tubulin in hypoxic adaptation. In particular, hypoxia-inducible factor 1-α (HIF1α) binds to an E-box motif located within the 3′UTR of *TUBB3* and induces its expression in ovarian cancer cells \[[@B127-ijms-18-01434]\]. Similarly, HIF1 and HIF2a interactions with overlapping HIF response elements within the *TUBB3* 3'UTR suppress and induce *TUBB3* expression in glioblastoma in normoxia and hypoxia, respectively \[[@B128-ijms-18-01434]\]. Hypoxic upregulation of βIII-tubulin expression in ovarian cancer cells is linked to increased HIF2α and SOX9 transcriptional activity \[[@B129-ijms-18-01434]\]. However, these effects are cell type specific, depend upon the epigenetic status of the *TUBB3* 3′UTR and are also influenced by the basal βIII-tubulin expression level \[[@B55-ijms-18-01434],[@B127-ijms-18-01434]\]. The expression of βIII-tubulin is also regulated by the interaction of the *TUBB3* transcript with the RNA binding protein Hu antigen (HuR) \[[@B130-ijms-18-01434]\], which is involved in the recruitment of mRNA transcripts to polysomes and has been demonstrated to be involved in HIF1α stabilization \[[@B131-ijms-18-01434]\]. Necrotic tumour regions have been shown to express high levels of βIII-tubulin, suggesting a functional role of βIII-tubulin in cellular adaptation to hypoxia \[[@B132-ijms-18-01434]\]. Whether altered expression of βIII-tubulin in response to hypoxia has functional consequences in promoting hypoxic adaptation is unknown.

4.2. Oxidative Stress and Microtubules {#sec4dot2-ijms-18-01434}
--------------------------------------

Oxidative stress depolymerises microtubules and reduces the microtubule assembly rate in cardiomyocytes and neurons \[[@B133-ijms-18-01434],[@B134-ijms-18-01434]\] suggesting that the microtubule cytoskeleton may play an important role in restoring redox balance. However, whether the microtubule network mediates redox homeostasis in cancer cells and in response to oxidative-stress inducing agents has not yet been demonstrated.

Comparative analysis of the structure of the different tubulin isotypes suggests that individual isotypes may contribute to cellular sensitivity to oxidative stress by acting as redox switches \[[@B135-ijms-18-01434]\]. These have been specifically identified in βIII-, βV- and βVI-tubulins wherein Ser/Ala124 has been substituted for cysteine, and Cys239 substitutes serine. These individual isotypes have been specifically identified as potential sensors of oxidative stress \[[@B135-ijms-18-01434]\]. Cys239 is readily oxidised and its oxidation inhibits microtubule assembly and stability \[[@B135-ijms-18-01434]\].

Hence, changes in tubulin isotype composition may influence microtubule stability in response to oxidative stress to support microtubule integrity and cell survival under a harsh tumour microenvironment.

Oxidative stress can be induced by the harsh tumour microenvironment, high metabolic activity of tumour cells and by radiation and chemotherapeutic treatments. DNA damaging agents are particularly reliant on the induction of oxidative stress for their efficacy \[[@B136-ijms-18-01434],[@B137-ijms-18-01434]\]. βIII-Tubulin and the DNA damage repair enzyme excision repair cross-complementation group-1 (ERCC1) co-operatively influence patient response to taxane combination therapy \[[@B41-ijms-18-01434]\], however the mechanisms underlying this co-operative effect are unknown. Direct interactions between βIII-tubulin and mediators of the oxidative stress response proteins glutathione S-transferase µ4 and dimethylaniline monooxygenase 4 have been reported in ovarian cancer cells \[[@B138-ijms-18-01434]\]. In neurons, suppression of βIII-tubulin expression sensitises cells to reactive oxygen species (ROS)-induced neurotoxicity in an isotype-specific manner, suggesting that it may protect cells from oxidative stress \[[@B139-ijms-18-01434]\]. Therefore, altered β-tubulin isotype expression in cancer may protect cells from oxidative stress to confer chemotherapy resistance and enable tumour progression.

4.3. Tubulin Isotypes and Metabolism {#sec4dot3-ijms-18-01434}
------------------------------------

Microtubules have been proposed to act as sensors of the energy state of the cell \[[@B140-ijms-18-01434],[@B141-ijms-18-01434]\], however the underlying mechanisms and involvement of specific tubulin isotypes is unclear. Recent studies have demonstrated that tubulin is capable of interacting with, and blocking the voltage dependent anion channel (VDAC) within the mitochondrial outer membrane, thereby regulating ATP and metabolite compartmentalisation to inhibit oxidative phosphorylation and promote glycolysis \[[@B142-ijms-18-01434],[@B143-ijms-18-01434],[@B144-ijms-18-01434],[@B145-ijms-18-01434],[@B146-ijms-18-01434]\]. Molecular dynamics simulations have revealed that an initial interaction between the tubulin body and VDAC is followed by insertion of the tubulin C-terminal tail within the channel lumen to regulate VDAC selectivity and voltage sensitivity \[[@B142-ijms-18-01434]\]. The different tubulin C-terminal tail sequences together with their associated post-translational modifications are likely to regulate the channel permeability and selectivity \[[@B142-ijms-18-01434],[@B145-ijms-18-01434],[@B147-ijms-18-01434]\]. VDAC is a component of the mitochondrial interactosome and regulates the mitochondrial membrane potential \[[@B148-ijms-18-01434]\] to influence the committal stages of apoptotic cell death \[[@B149-ijms-18-01434]\] and the overall potential for cells to proceed towards cell death in response to stimuli.

The general ability of tubulin proteins to bind to a range of glycolytic enzymes and regulate their activity as well as to reciprocally influence microtubule dynamics has been well established in cell-free systems \[[@B150-ijms-18-01434],[@B151-ijms-18-01434],[@B152-ijms-18-01434],[@B153-ijms-18-01434],[@B154-ijms-18-01434],[@B155-ijms-18-01434],[@B156-ijms-18-01434],[@B157-ijms-18-01434],[@B158-ijms-18-01434],[@B159-ijms-18-01434],[@B160-ijms-18-01434]\] and in ovarian cancer cells \[[@B138-ijms-18-01434]\] but clarity on the influence of specific isotypes and the functional implications of these interactions has been lacking. A more recent study in NSCLC cells indicates that βIII-tubulin functionally impacts glucose metabolism by suppressing glycolytic metabolism and reduces the reliance of these cells on glycolysis \[[@B161-ijms-18-01434]\]. A study by Cicchillitti and colleagues has also pointed to a role for βIII-tubulin in glucose metabolism stress \[[@B138-ijms-18-01434]\]. βIII-tubulin is upregulated in ovarian cancer cells treated with tunicamycin or wortmannin, to block protein glycosylation and PI3K signalling, respectively. Tunicamycin and wortmannin treatment also alters post-translational modifications of non-mitochondrial tubulins in cell lines with low basal βIII-tubulin expression \[[@B138-ijms-18-01434]\]. In addition, ovarian cancer cells under glucose starvation have been shown to have an increased expression of βIII-tubulin and a decreased expression of βI-tubulin \[[@B130-ijms-18-01434]\]. Upregulation of βIII-tubulin in these conditions correlates with HuR binding to the βIII-tubulin 3'UTR in ovarian cancer cells \[[@B130-ijms-18-01434]\]. Moreover, βIII-tubulin expression promotes cell survival and proliferation in glucose-starved NSCLC cells \[[@B161-ijms-18-01434]\]. Mechanistic detail of the role of this and other β-tubulin isotypes in regulating cancer cell metabolism remains to be fully defined \[[@B130-ijms-18-01434]\].

4.4. Tubulin Isotypes and Mitochondrial Function {#sec4dot4-ijms-18-01434}
------------------------------------------------

The microtubule network regulates the mitochondrial membrane potential and mitochondrial trafficking by as yet undefined mechanisms \[reviewed in \[[@B162-ijms-18-01434]\]\]. Tubulin is an integral component of mitochondrial membranes \[[@B143-ijms-18-01434],[@B144-ijms-18-01434],[@B163-ijms-18-01434]\], and these membranes are enriched with βIII-tubulin \[[@B138-ijms-18-01434],[@B144-ijms-18-01434],[@B164-ijms-18-01434]\]. An important role for this isotype in mitochondrial dynamics and function is suggested from interactions between βIII-tubulin and GRP75 and mitochondrial-localised Hsp70 in Ovarian cancer cells \[[@B138-ijms-18-01434]\]. Post-translational mechanisms are thought to regulate tubulin localization to mitochondria, with a non-phosphorylated and non-glycosylated form of βIII-tubulin present in mitochondria \[[@B138-ijms-18-01434]\], however there was no correlation between high levels of mitochondrial βIII-tubulin localisation and tubulin binding agent resistance \[[@B138-ijms-18-01434]\]. Further functional studies defining the importance of these protein--protein interactions and post-translational modifications are warranted.

Mitochondrial dynamics can significantly impact tumour progression \[[@B165-ijms-18-01434],[@B166-ijms-18-01434]\] and growing evidence supports a role for the βII- and βIII-tubulin isotypes in regulating these complex processes. The βII-tubulin isotype is involved in mitochondrial localisation and metabolism in cardiomyocytes \[[@B167-ijms-18-01434],[@B168-ijms-18-01434],[@B169-ijms-18-01434],[@B170-ijms-18-01434]\]. The βIII-tubulin C-terminal tail reduces kinesin-1 processivity and alters kinesin-1 force production in an isotype specific manner \[[@B171-ijms-18-01434],[@B172-ijms-18-01434]\] and kinesin-1 is an important mediator of mitochondrial localisation \[[@B173-ijms-18-01434],[@B174-ijms-18-01434]\]. Mutations within helix 12 of tubulin adjacent to the βIII-tubulin C-terminal tail also results in neurodevelopmental defects that are similar to those caused by kinesin mutations and abnormal mitochondrial trafficking \[[@B175-ijms-18-01434],[@B176-ijms-18-01434],[@B177-ijms-18-01434],[@B178-ijms-18-01434]\]. Evaluation of the contribution of these two isotypes in mitochondrial dynamics may reveal functional implications for these proteins in disease progression and chemotherapy sensitivity \[[@B179-ijms-18-01434]\].

4.5. Tubulin Isotypes and Endoplasmic Reticulum Stress {#sec4dot5-ijms-18-01434}
------------------------------------------------------

Tubulins are known to regulate endoplasmic reticulum (ER) homeostasis, with ER dynamics tightly linked to microtubule dynamics \[[@B180-ijms-18-01434],[@B181-ijms-18-01434],[@B182-ijms-18-01434],[@B183-ijms-18-01434],[@B184-ijms-18-01434],[@B185-ijms-18-01434],[@B186-ijms-18-01434]\]. This is particularly important during ER stress, as expansion of the ER is one mechanism of relieving ER stress \[[@B187-ijms-18-01434],[@B188-ijms-18-01434]\], however the involvement of specific tubulin isotypes in regulating ER stress is unclear. Suppression of βIII-tubulin expression promotes ER stress in response to glucose starvation, and in doing so promotes cell death and reduces cell proliferation \[[@B161-ijms-18-01434]\]. βIII-Tubulin interacts with the master regulator of the ER stress response GRP78 in ovarian and NSCLC cancer cells \[[@B138-ijms-18-01434],[@B161-ijms-18-01434]\] and influences the formation of a complex between AKT and GRP78 in response to glucose starvation \[[@B161-ijms-18-01434]\], raising the possibility that it may play a role in maintaining the protein processing capacity of the ER to support continued cell growth in the harsh tumour microenvironment. Increasing recognition of the role of ER stress and the ER stress response in regulating chemotherapeutic efficacy and tumour progression \[[@B189-ijms-18-01434],[@B190-ijms-18-01434],[@B191-ijms-18-01434]\] highlights that an involvement for tubulin isotypes in regulating these processes may enable drug resistance and promote tumour progression.

4.6. Tubulin Isotypes and Autophagy {#sec4dot6-ijms-18-01434}
-----------------------------------

The microtubule network is involved in the initiation and execution of macroautophagy (reviewed in \[[@B162-ijms-18-01434]\]), which is an important regulator of cancer cell survival and their treatment sensitivity. The autophagy machinery operates in a highly concerted manner to sequester cytoplasmic components within an autophagosome and regulate the fusion of this autophagosome with lysosome to degrade its contents \[[@B192-ijms-18-01434]\]. Recent studies have suggested a role for autophagy in regulating cancer cell survival and treatment sensitivity and reviews have covered this topic in detail \[[@B193-ijms-18-01434],[@B194-ijms-18-01434],[@B195-ijms-18-01434]\]. Microtubules sequester autophagic components to regulate the initiation of autophagy \[[@B196-ijms-18-01434],[@B197-ijms-18-01434],[@B198-ijms-18-01434],[@B199-ijms-18-01434],[@B200-ijms-18-01434]\], are involved in autophagosome trafficking \[[@B198-ijms-18-01434]\] and in the fusion of autophagosomes with lysosomes to complete the pathway \[[@B201-ijms-18-01434],[@B202-ijms-18-01434],[@B203-ijms-18-01434]\]. It has also been suggested that microtubules facilitate autophagosome formation. Dynamics of microtubules play a major role in the regulation of starvation-induced \[[@B198-ijms-18-01434],[@B202-ijms-18-01434]\] autophagosome formation but not in basal conditions \[[@B202-ijms-18-01434],[@B204-ijms-18-01434],[@B205-ijms-18-01434]\]. Although the involvement of particular tubulin isotypes in these processes is unclear, a recent study proposed βIII-tubulin as a binding partner with the key autophagic mediator LC3 \[[@B206-ijms-18-01434]\]. The functional significance of this association, and indeed a role for other tubulin isotypes in autophagy, remain to be defined.

5. Tubulin and Metastasis {#sec5-ijms-18-01434}
=========================

A growing body of evidence has pointed to a role for the tubulin proteins in the metastatic progression of cancer. Research conducted over the past decade has indicated several tubulin isotypes as potential prognostic markers whose expression levels in primary tumours are associated with aggressive disease with greater metastatic potential and the propensity of patients to suffer metastatic relapse, although the major focus has centred on βIII-tubulin expression. In particular, clinical data has identified that high βIII-tubulin protein expression strongly correlates with aggressive clinical behaviour and poor patient outcome in many forms of cancer, including breast, ovarian, gastric, glioblastoma, prostate, colorectal, pancreatic and NSCLC \[[@B39-ijms-18-01434],[@B47-ijms-18-01434],[@B66-ijms-18-01434],[@B121-ijms-18-01434],[@B132-ijms-18-01434],[@B207-ijms-18-01434],[@B208-ijms-18-01434],[@B209-ijms-18-01434],[@B210-ijms-18-01434],[@B211-ijms-18-01434],[@B212-ijms-18-01434],[@B213-ijms-18-01434]\]. βIII-Tubulin expression is associated with high-grade malignancy in gliomas and gastric cancers \[[@B47-ijms-18-01434],[@B132-ijms-18-01434],[@B208-ijms-18-01434],[@B209-ijms-18-01434],[@B214-ijms-18-01434],[@B215-ijms-18-01434]\]. Similarly, in NSCLC, expression of βIII-tubulin is associated with higher histological grades, poorly differentiated tumour tissue and progression to metastatic disease \[[@B39-ijms-18-01434],[@B207-ijms-18-01434],[@B211-ijms-18-01434],[@B212-ijms-18-01434]\]. High βIII-tubulin expression is also detected at the invasive tumour edge of atypical carcinoid lung cancers \[[@B211-ijms-18-01434]\], in lymph node metastases from primary adenocarcinoma NSCLC \[[@B216-ijms-18-01434]\] and in metastatic lung cancers derived from colon, prostate and ovarian tumours but not from primary tumours of the breast \[[@B211-ijms-18-01434]\]. In colorectal cancer, the expression of βIII-tubulin expression also correlates with high grade malignancy, tumour differentiation and lymphatic metastasis, suggesting a potential role of βIII-tubulin in prostate tumour differentiation and metastasis \[[@B213-ijms-18-01434]\]. Overexpression of βIII-tubulin is observed in breast cancer brain metastases and its expression is significantly associated with distant metastases \[[@B121-ijms-18-01434]\]. Furthermore, in prostate cancer, βIII-tubulin expression is associated with both *TMPRSS2:ERG* rearrangement, ERG expression and *PTEN* deletions, three key oncogenetic features in metastatic prostate cancer \[[@B48-ijms-18-01434]\].

In melanoma, βIIb-tubulin mRNA transcript levels were significantly elevated in melanoma multinucleated giant cells which are frequently observed in metastatic sites and correlate with poor prognosis, indicating that this tubulin isotype may play an important role in melanoma metastasis \[[@B217-ijms-18-01434]\]. Increased expression of βIVb-tubulin was observed in sentinel lymph node micrometastasis of colorectal cancer \[[@B218-ijms-18-01434]\]. Similarly, in lung cancer cells, βIVa-tubulin expression is induced under non-adherent conditions, which resemble those experienced by circulating tumour cells \[[@B219-ijms-18-01434]\].

Tumour metastasis requires completion of a multistep process, with dissemination of cancer cells into distant organ sites and their subsequent adaptation to foreign tissue microenvironments. Altered tubulin isotype composition may increase the metastatic potential of cancer cells by altering their capacity for migration and invasion. Emerging evidence indicates that activation of the epithelial-to-mesenchymal transition (EMT) program is critical in regulating invasion and metastasis \[[@B220-ijms-18-01434]\] and that EMT reprogramming is influenced by the tubulin isotype composition. In particular, βIII-tubulin expression correlates with Snail expression levels and modulates the behaviour of Snail overexpression during EMT transition in colon cancer cells \[[@B221-ijms-18-01434]\]. Knockdown of βIII-tubulin expression using RNA interference agents caused modulation of colon cancer cell movement and a decrease in their ability to migrate and invade \[[@B221-ijms-18-01434]\]. Similarly, in breast cancer, a positive feedback regulation of ZEB1 and β-tubulin isotype classes I, III, and IVB has been reported \[[@B71-ijms-18-01434]\]. Knockdown of ZEB1 in human breast cancer cells reduces β-tubulin isotype classes I, III, and IVB mRNA, whereas upregulation of ZEB1 was associated with increases in these isotype classes. This finding suggests that βIII-tubulin is a biomarker for cell survival mediated through ZEB1-induced EMT that contributes to the aggressive tumour phenotype in breast cancer.

Functional links between βIII-tubulin and metastasis have also been reported using lung and pancreatic cancer mouse models \[[@B63-ijms-18-01434],[@B66-ijms-18-01434],[@B123-ijms-18-01434]\]. Knockdown of βIII-tubulin decreases anchorage independent growth, a major phenotype with respect to metastatic potential, in NSCLC cells \[[@B63-ijms-18-01434]\]. βIII-tubulin suppression upregulates the adhesion-associated tumour suppressor Maspin, inhibits tumour spheroid outgrowth, cell migration, and sensitises NSCLC cells to anoikis \[[@B123-ijms-18-01434]\]. Silencing βIII-tubulin expression also reduced pancreatic cancer cell growth, tumorigenic potential and metastatic burden \[[@B66-ijms-18-01434]\]. Similarly, Kanojia and colleagues \[[@B121-ijms-18-01434]\] demonstrated a role for βIII-tubulin in conferring brain metastatic potential to breast cancer cells by regulating several key signalling molecules involved in cell adhesion and metastasis \[[@B121-ijms-18-01434]\]. Suppression of βIII-tubulin expression regulated the expression of L1CAM and β3-integrin to reduce extracellular matrix (ECM) attachment and signalling through the β3-integrin/(focal adhesion kinase) FAK/Src pathway in vitro. This was associated with reduced metastatic ability in vivo and improved survival in a brain metastasis model \[[@B121-ijms-18-01434]\]. Overall, these findings imply a role of tubulin isotypes, in particular βIII-tubulin, as mediators of metastasis and may be potential predictive markers for neoplastic progression and patient outcome. However, the mechanisms by which βIII-tubulin regulate the metastatic cascade remain to be fully determined.

6. Conclusions {#sec6-ijms-18-01434}
==============

The aberrant expression of β-tubulin isotypes in a range of cancers is correlated with aggressive, drug refractory disease with poor clinical outcome. While the effect of isotype composition on the interaction of tubulin binding agents with their targets, and on microtubule dynamics may partially explain drug resistance to these classes of common chemotherapeutics, the current evidence suggests that tubulin isotypes are involved more broadly in biological processes that modulate tumour progression and metastasis. Through interactions with oncogenic signalling and cell survival programs that facilitate adaptation to the harsh tumour microenvironment, altered tubulin isotype composition in cancer may contribute to drug resistance and more aggressive disease ([Figure 1](#ijms-18-01434-f001){ref-type="fig"}). Defining the complex interplay of factors that regulate the spatiotemporal localisation and function of tubulin isotypes would significantly contribute to dissecting the mechanisms by which the tubulin isotype composition impacts tumour biology and treatment resistance in cancer.

In order to develop a more comprehensive understanding of the tubulin code in cancer, the context in which tubulin isotypes impact clinical outcome in this disease will need to be more robustly defined both within and between different types of cancers. Critical to this will be a firm understanding of the mechanisms that drive the individual and collective expression of tubulin isotypes in health and disease. The advent of gene-editing technologies provides great potential in the selective manipulation of isotype expression while retaining the endogenous regulatory framework. Defining the larger intracellular network in which the microtubule system operates will no doubt reveal the complex integration of this component of the cytoskeletal network with fundamental cellular processes and reveal novel therapeutic strategies for targeting altered tubulin isotype expression in cancer.
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###### 

Clinical studies of tubulin isotypes in drug resistance.

  Alteration of Tubulin Isotype                                                                                         Effect                                                                                        Tumour Type                                                                                                                                                                                        Reference
  --------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  High βI-tubulin                                                                                                       Poor response to docetaxel treatment                                                          Breast cancer                                                                                                                                                                                      \[[@B17-ijms-18-01434]\]
  Low βII-tubulin expression                                                                                            Correlates with poor response to taxane treatment or advanced stage disease                   Breast and ovarian cancer                                                                                                                                                                          \[[@B19-ijms-18-01434],[@B22-ijms-18-01434]\]
  High βIII-tubulin expression                                                                                          Poor survival, poor outcome for surgical resection or TBA response; Correlates with subtype   Non-small cell lung cancer (NSCLC)                                                                                                                                                                 \[[@B24-ijms-18-01434],[@B25-ijms-18-01434],[@B37-ijms-18-01434],[@B38-ijms-18-01434],[@B39-ijms-18-01434],[@B40-ijms-18-01434],[@B41-ijms-18-01434],[@B42-ijms-18-01434],[@B43-ijms-18-01434],[@B44-ijms-18-01434],[@B45-ijms-18-01434]\]
  Correlates with poor survival, poor response to platinum and taxane treatment, advanced stage or aggressive disease   Ovarian cancer                                                                                \[[@B19-ijms-18-01434],[@B20-ijms-18-01434],[@B21-ijms-18-01434],[@B28-ijms-18-01434],[@B29-ijms-18-01434],[@B30-ijms-18-01434],[@B31-ijms-18-01434],[@B32-ijms-18-01434],[@B33-ijms-18-01434]\]   
  Favourable response to taxane treatment                                                                               Ovarian (Clear cell adenocarcinoma)                                                           \[[@B34-ijms-18-01434]\]                                                                                                                                                                           
  Poor response to taxane treatment                                                                                     Breast cancer                                                                                 \[[@B17-ijms-18-01434],[@B46-ijms-18-01434]\]                                                                                                                                                      
  Poor response to taxane/platinum treatment                                                                            Uterine serous carcinoma                                                                      \[[@B18-ijms-18-01434]\]                                                                                                                                                                           
  Poor response to taxane treatment                                                                                     Gastric cancer                                                                                \[[@B26-ijms-18-01434],[@B47-ijms-18-01434]\]                                                                                                                                                      
  Advanced disease and early recurrence                                                                                 Prostate cancer                                                                               \[[@B48-ijms-18-01434]\]                                                                                                                                                                           
  High βIVa-tubulin expression                                                                                          Poor response to taxol treatment                                                              Ovarian cancer                                                                                                                                                                                     \[[@B29-ijms-18-01434]\]
  High βV-tubulin expression                                                                                            Favourable response to taxane treatment                                                       NSCLC                                                                                                                                                                                              \[[@B27-ijms-18-01434]\]

[^1]: These Authors contributed equally to this work.
